Abstract:This study introduces on‐line ultra‐performance liquid chromatography (UPLC) and multi‐mode fluorescence spectroscopy (MMFS) as innovative analytical technologies for characterizing co‐formulated monoclonal antibodies (mAbs). By measuring critical quality attributes (CQAs) efficiently, these methods significantly reduce analytical turnaround time and enhance manufacturing processes. On‐line UPLC offers automated and precise measurements, while MMFS provides a rapid, cost‐effective alternative for simultaneous CQA assessment. Together, they support the pharmaceutical industry's need for expedited clinical development and improved product quality in biopharmaceutical manufacturing. Characterizing co‐formulated monoclonal antibodies (mAbs) poses significant challenges in the pharmaceutical industry. Due to the high structural similarity of the mAbs, traditional analytical methods, compounded by the lengthy method development process, hinder product development and manufacturing efficiency. There is increasing critical need in the pharmaceutical industry to streamline analytical approaches, minimizing time and resources, ensuring a rapid clinical entry and cost‐effective manufacturing. This study investigates the application of process analytical technologies (PAT) to address such challenges. Our investigation introduces two complementary technologies, on‐line ultra‐performance liquid chromatography (online UPLC) and multimode fluorescence spectroscopy (MMFS), as potential PAT tools tailored for characterizing critical quality attributes (CQA) in co‐formulated mAb products. Specifically, the CQAs under evaluation include the total protein concentration of the mAbs within the co‐formulation and the ratio of mAb A to mAb B. Online UPLC enables direct and automated measurement of the CQAs through physical separation, while MMFS determines them in a non‐destructive and more swift manner based on chemometric modeling. We demonstrate these technologies' comparable performance to conventional methods, alongside substantial benefits such as reduced analytical turnaround time and decreased laboratory efforts. Ultimately, integrating them as innovative PAT tools expedites the delivery of therapeutic solutions to patients and enhances manufacturing efficiency, aligning with the imperative for swift translation of scientific discoveries into clinical benefits.

Convolutional Neural Networks Guided Raman Spectroscopy as a Process Analytical Technology (PAT) Tool for Monitoring and Simultaneous Prediction of Monoclonal Antibody Charge Variants

Raman Spectroscopy As Process Analytical Tool in Downstream Processing of Biotechnology

UV/Vis-based process analytical technology to improve monoclonal antibody and host cell protein separation

Comparison of UV‐ and Raman‐based monitoring of the Protein A load phase and evaluation of data fusion by PLS models and CNNs

Machine learning for classification and quantification of monoclonal antibody preparations for cancer therapy

Rapid analysis of titer, aggregate, and intact mass of antibody therapeutics using automated multi-dimensional liquid chromatography coupled with native mass spectroscopy

Multiattribute Monitoring of Antibody Charge Variants by Cation-Exchange Chromatography Coupled to Native Mass Spectrometry

Implemention of Innovative Process Analytical Technologies to Characterize Critical Quality Attributes of Co‐Formulated Monoclonal Antibody Products

Automated calibration and in‐line measurement of product quality during therapeutic monoclonal antibody purification using Raman spectroscopy

Targeted CQA analytical control strategy for commercial antibody products: Replacing ion-exchange chromatography methods for charge heterogeneity with multi-attribute monitoring

A Review of 1D Convolutional Neural Networks toward Unknown Substance Identification in Portable Raman Spectrometer

Raman Spectroscopy to Monitor Post-Translational Modifications and Degradation in Monoclonal Antibody Therapeutics

Use of Raman spectroscopy and PCA for quality evaluation and out-of-specification identification in biopharmaceutical products

Pioneering Just-in-Time (JIT) Strategy for Accelerating Raman Method Development and Implementation for Biologic Continuous Manufacturing

Affinity-Resolved Size Exclusion Chromatography Coupled to Mass Spectrometry: A Novel Tool to Study the Attribute-and-Function Relationship in Therapeutic Monoclonal Antibodies

Generative data augmentation and automated optimization of convolutional neural networks for process monitoring

A novel method for continuous chromatographic separation of monoclonal antibody charge variants by combining displacement mode chromatography and step elution

Comprehensive Multidimensional Liquid Chromatography-Mass Spectrometry for the Characterization of Charge Variants of a Bispecific Antibody

Offline Coupling of Hydrophobic Interaction Chromatography–Capillary Zone Electrophoresis for Monitoring Charge‐Based Heterogeneity of Recombinant Monoclonal Antibodies

Monitoring mAb cultivations with in-situ raman spectroscopy: The influence of spectral selectivity on calibration models and industrial use as reliable PAT tool

Simultaneous prediction of 16 quality attributes during protein A chromatography using machine learning based Raman spectroscopy models